Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma

Signaling Pathway Mediating Myeloma Cell Growth and Survival

(2021) Teru Hideshima et al.   Cancers

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma

(2020) Erin Flynt et al.   Cells

Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management

(2020) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance

(2020) Matthew Ho et al.   Clinical Lymphoma Myeloma & Leukemia

Selinexor for advanced hematologic malignancies

(2020) Janek S. Walker et al.   LEUKEMIA & LYMPHOMA

Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma

(2020) Fazal Shirazi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection

(2020) Panagiotis Malandrakis et al.   OncoTargets and Therapy

Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma

(2020) Charles Marusak et al.   CLINICAL CANCER RESEARCH

The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy

(2020) Jimin Yuan et al.   Journal of Hematology & Oncology

Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer

(2020) Oliver J. Pickles et al.   Oncotarget

Emerging protein kinase inhibitors for the treatment of multiple myeloma

(2019) Judith Lind et al.   EXPERT OPINION ON EMERGING DRUGS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Resistance to proteasome inhibitors and other targeted therapies in myeloma

(2018) Craig T. Wallington-Beddoe et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Blocking Ras inhibition as an antitumor strategy

(2018) Nagore I. Marín-Ramos et al.   SEMINARS IN CANCER BIOLOGY

Critical role of FOXO3a in carcinogenesis

(2018) Ying Liu et al.   Molecular Cancer

Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor

(2018) Vinod Vijay Subhash et al.   Scientific Reports

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways

(2018) Benoît Tessoulin et al.   Journal of Hematology & Oncology

The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy

(2016) Jing Lu et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Progress and Paradigms in Multiple Myeloma

(2016) Kenneth C. Anderson   CLINICAL CANCER RESEARCH

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

(2016) N Majithia et al.   LEUKEMIA

Type I insulin-like growth factor receptor signaling in hematological malignancies

(2016) Deeksha Vishwamitra et al.   Oncotarget

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma

(2016) Joel G. Turner et al.   Oncotarget

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

(2015) S Ozaki et al.   Blood Cancer Journal

Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

(2015) Rikio Suzuki et al.   PLoS One

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

(2013) C Chang-Yew Leow et al.   Blood Cancer Journal

Blockade of XBP1 splicing by inhibition of IRE1  is a promising therapeutic option in multiple myeloma

(2012) N. Mimura et al.   BLOOD

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

Cardiac Hypertrophy Is Positively Regulated by MicroRNA miR-23a

(2011) Kun Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

(2010) Jessie Villanueva et al.   CANCER CELL

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

(2010) Diana Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

(2008) J. Tsai et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA